{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:13:29Z","timestamp":1791267209345,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"am","delay-in-days":335,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031022","name":"Center for Cancer Research","doi-asserted-by":"publisher","award":["ZIA BC 011513"],"award-info":[{"award-number":["ZIA BC 011513"]}],"id":[{"id":"10.13039\/100031022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.canlet.2023.216606","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T02:25:45Z","timestamp":1705976745000},"page":"216606","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Near-infrared photoimmunotherapy targeting Nectin-4 in a preclinical model of bladder cancer"],"prefix":"10.1016","volume":"585","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7548-1580","authenticated-orcid":false,"given":"Hiroshi","family":"Fukushima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichiro","family":"Takao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1339-4219","authenticated-orcid":false,"given":"Aki","family":"Furusawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Valera Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Gurram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Kano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Choyke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1019-4112","authenticated-orcid":false,"given":"Hisataka","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2023.216606_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.canlet.2023.216606_bib2","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.euo.2020.12.002","article-title":"Prognostic value of the WHO1973 and WHO2004\/2016 classification systems for grade in primary Ta\/T1 non-muscle-invasive bladder cancer: a multicenter European association of urology non-muscle-invasive bladder cancer guidelines panel study","volume":"4","author":"van Rhijn","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.canlet.2023.216606_bib3","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.euf.2020.01.006","article-title":"Significance of bladder neck involvement in risk substratification of intermediate-risk non-muscle-invasive bladder cancer","volume":"7","author":"Fukushima","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.canlet.2023.216606_bib4","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/JU.0000000000002740","article-title":"Sequential intravesical gemcitabine and docetaxel for bacillus calmette-guerin-naive high-risk nonmuscle-invasive bladder cancer","volume":"208","author":"McElree","year":"2022","journal-title":"J. Urol."},{"key":"10.1016\/j.canlet.2023.216606_bib5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00345-009-0395-z","article-title":"Economic aspects of bladder cancer: what are the benefits and costs?","volume":"27","author":"Sievert","year":"2009","journal-title":"World J. Urol."},{"key":"10.1016\/j.canlet.2023.216606_bib6","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2023.216606_bib7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2023.216606_bib8","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1200\/JCO.19.01213","article-title":"Long-Term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer","volume":"38","author":"Vuky","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2023.216606_bib9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1080\/14737140.2022.2069563","article-title":"Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma","volume":"22","author":"Mantia","year":"2022","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.canlet.2023.216606_bib10","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/1078-0432.CCR-20-2275","article-title":"FDA approval summary: enfortumab vedotin for locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Chang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2023.216606_bib11","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","article-title":"Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin","volume":"27","author":"Chu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2023.216606_bib12","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.urolonc.2021.05.013","article-title":"New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer - what do we understand so far?","volume":"39","author":"Hoffman-Censits","year":"2021","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.canlet.2023.216606_bib13","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.euo.2021.11.005","article-title":"TROP2 expression across molecular subtypes of urothelial carcinoma and enfortumab vedotin-resistant cells","volume":"5","author":"Chou","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.canlet.2023.216606_bib14","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance","volume":"29","author":"Klumper","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2023.216606_bib15","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3390\/cancers11030394","article-title":"Acquired resistance to antibody-drug conjugates","volume":"11","author":"Collins","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2023.216606_bib16","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1158\/1078-0432.CCR-21-1807","article-title":"NECTIN4 heterogeneity and molecular diversity in bladder cancers: deconstructing the activity of an antibody-drug conjugate","volume":"27","author":"Teo","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2023.216606_bib17","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1021\/acs.accounts.9b00273","article-title":"Near-infrared photoimmunotherapy of cancer","volume":"52","author":"Kobayashi","year":"2019","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.canlet.2023.216606_bib18","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1038\/nm.2554","article-title":"Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules","volume":"17","author":"Mitsunaga","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2023.216606_bib19","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.3390\/cancers14122996","article-title":"Near-infrared photoimmunotherapy (NIR-PIT) in urologic cancers","volume":"14","author":"Fukushima","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2023.216606_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf6843","article-title":"Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy","volume":"8","author":"Sato","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2023.216606_bib21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jconrel.2018.04.027","article-title":"3D mesoscopic fluorescence tomography for imaging micro-distribution of antibody-photon absorber conjugates during near infrared photoimmunotherapy in vivo","volume":"279","author":"Tang","year":"2018","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.canlet.2023.216606_bib22","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1021\/acscentsci.8b00565","article-title":"Photoinduced ligand release from a silicon phthalocyanine dye conjugated with monoclonal antibodies: a mechanism of cancer cell cytotoxicity after near-infrared photoimmunotherapy","volume":"4","author":"Sato","year":"2018","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.canlet.2023.216606_bib23","doi-asserted-by":"crossref","first-page":"104295","DOI":"10.18632\/oncotarget.22223","article-title":"Dynamic changes in the cell membrane on three dimensional low coherent quantitative phase microscopy (3D LC-QPM) after treatment with the near infrared photoimmunotherapy","volume":"8","author":"Ogata","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2023.216606_bib24","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3390\/pharmaceutics14020241","article-title":"EGFR-targeted photodynamic therapy","volume":"14","author":"Ulfo","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.canlet.2023.216606_bib25","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1158\/1078-0432.CCR-18-3267","article-title":"CD47-Targeted near-infrared photoimmunotherapy for human bladder cancer","volume":"25","author":"Kiss","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2023.216606_bib26","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1111\/cas.15013","article-title":"Endoscopic near-infrared photoimmunotherapy in an orthotopic head and neck cancer model","volume":"112","author":"Okada","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2023.216606_bib27","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/cas.14809","article-title":"Diagnostic imaging in near-infrared photoimmunotherapy using a commercially available camera for indocyanine green","volume":"112","author":"Inagaki","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2023.216606_bib28","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2023.216606_bib29","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2023.216606_bib30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/path.4886","article-title":"Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification","volume":"242","author":"Sjodahl","year":"2017","journal-title":"J. Pathol."},{"key":"10.1016\/j.canlet.2023.216606_bib31","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","article-title":"An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer","volume":"12","author":"Lindskrog","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2023.216606_bib32","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3233\/BLC-180167","article-title":"Systematic review: characteristics and preclinical uses of bladder cancer cell lines","volume":"4","author":"Zuiverloon","year":"2018","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.canlet.2023.216606_bib33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/978-1-62703-290-2_7","article-title":"Detection of necrosis by release of lactate dehydrogenase activity","volume":"979","author":"Chan","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.canlet.2023.216606_bib34","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1111\/cas.15466","article-title":"Intercellular adhesion molecule-1-targeted near-infrared photoimmunotherapy of triple-negative breast cancer","volume":"113","author":"Fukushima","year":"2022","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2023.216606_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/PLPU1526","article-title":"Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: photo rct","volume":"26","author":"Heer","year":"2022","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.canlet.2023.216606_bib36","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.2147\/NDT.S78182","article-title":"Near-infrared photonic energy penetration: can infrared phototherapy effectively reach the human brain?","volume":"11","author":"Henderson","year":"2015","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.canlet.2023.216606_bib37","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.eururo.2021.10.009","article-title":"A molecular inquiry into the role of antibody-drug conjugates in Bacillus calmette-guerin-exposed non-muscle-invasive bladder cancer","volume":"81","author":"Choi","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2023.216606_bib38","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts general hospital experience","volume":"71","author":"Giacalone","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2023.216606_bib44","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2326-6066.CIR-18-0546","article-title":"Host immunity following near-infrared photoimmunotherapy is enhanced with PD-1 checkpoint blockade to eradicate established antigenic tumors","volume":"7","author":"Nagaya","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.canlet.2023.216606_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103345","article-title":"Near-infrared photoimmunotherapy targeting human-EGFR in a mouse tumor model simulating current and future clinical trials","volume":"67","author":"Okada","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.canlet.2023.216606_bib40","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.2019922","article-title":"CD29 targeted near-infrared photoimmunotherapy (NIR-PIT) in the treatment of a pigmented melanoma model","volume":"11","author":"Furusawa","year":"2022","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2023.216606_bib41","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1158\/1535-7163.MCT-23-0210","article-title":"Intratumoral IL15 improves efficacy of near-infrared photoimmunotherapy","volume":"22","author":"Fukushima","year":"2023","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2023.216606_bib42","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1158\/1535-7163.MCT-16-0924","article-title":"Epidermal growth factor receptor (EGFR)-targeted photoimmunotherapy (PIT) for the treatment of EGFR-expressing bladder cancer","volume":"16","author":"Railkar","year":"2017","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2023.216606_bib43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1158\/1535-7163.MCT-22-0313","article-title":"Near-infrared photoimmunotherapy targeting podoplanin-expressing cancer cells and cancer-associated fibroblasts","volume":"22","author":"Kato","year":"2023","journal-title":"Mol. Cancer Therapeut."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383523005578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383523005578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:35:11Z","timestamp":1719621311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383523005578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":44,"alternative-id":["S0304383523005578"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2023.216606","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Near-infrared photoimmunotherapy targeting Nectin-4 in a preclinical model of bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2023.216606","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"216606"}}